Eugene Rossitch III, MHA, has been named administrative director for Duke Cancer Institute’s Gastrointestinal (GI), Sarcoma and Melanoma disease groups. In his new role, Rossitch will provide overall administrative leadership for the groups.
“We are pleased that Eugene has accepted the role of administrative director for the GI, Sarcoma and Melanoma oncology disease groups,” said Laura Sample, MHA, assistant vice president, clinical programs, Duke Cancer Institute. “Eugene’s experience in healthcare administration operations, and strategic planning at Duke is very valuable and will help to further advance these programs.”
Rossitch most recently served as administrative manager in the Department of Orthopaedic Surgery at Duke Health. In that role, which he assumed in 2016, Rossitch was the divisional administrator supporting Spine, Joint, Hand, Foot and Ankle and Trauma, Pediatrics, Oncology, Hip through local level strategic business, programmatic and operational planning. Rossitch also oversaw the onboarding for incoming faculty and advanced practice providers (APP) and managed 15 administrative assistants.
Previously, from July 2014 to July 2016, Rossitch served as senior planning analyst for Duke Health Strategic Planning where, among other duties, he managed the Sports Medicine strategic planning process. He also worked as a business planner in Strategic Planning and Development at Novant Health, from February 2011 to May 2013.
Rossitch received his Bachelor of Arts degree in Political Science from the University of North Carolina at Chapel Hill. He received his Master of Healthcare Administration from the University of North Carolina at Chapel Hill in 2011.
“I am thrilled to be joining the Duke Cancer Institute team,” said Rossitch. “I look forward to working with my administrative colleagues and the physician leads for GI, Melanoma, and Sarcoma to provide the highest-quality care for our patients and identifying opportunities to enhance our services.”
Rossitch assumed his new role as administrative director for the GI, Sarcoma and Melanoma disease groups on Dec. 3.